LabCorp expands drug monitoring portfolio

LabCorp Diagnostics (NYSE: LH), the Burlington-based lab testing giant, is expanding its therapeutic drug monitoring portfolio with a new investigative assessment to monitor a drug that treats inflammatory diseases such as rheumatoid arthritis and Crohn's disease. The DoseAssure CTZ assay is LabCorp's latest addition to its therapeutic drug monitoring menu. It will track a study that allows physicians to monitor patients on the drug Certolizumab. “Biologic drugs can be life-changing, but individual…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news